


Evaluation of AD on Prescribing Patterns for Attention-Deficit/Hyperactivity Disorder

Jacki Travers, Pharm.D.
Academic Detailing Pharmacist

Pharmacy Management Consultants
Oklahoma City, OK



Disclosures

- No conflicts of interest
- External funding: Health Service Initiative through the Children's Health Program (CHIP)
- Employed by the University of Oklahoma, College of Pharmacy
- Academic Detailer for Oklahoma Medicaid providers

Collaborative Advancement of
Prescription Excellence
CARE

Background

ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents

American Academy
of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN™

AMERICAN ACADEMY OF
CHILD & ADOLESCENT
PSYCHIATRY

WWW.AACAP.ORG



Centers for Disease Control and Prevention

CDC 24/7: Saving Lives, Protecting People™


ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management. Pediatrics Oct 2011, peds.2011-2654. Available at: <http://pediatrics.aappublications.org/content/128/5/1007>. Accessed October 18, 2017.

Vital Signs: National and State-Specific Patterns of Attention Deficit/Hyperactivity Disorder Treatment Among Insured Children Aged 2–5 Years —United States, 2008–2014. Visser SN, Danielson ML, Wolraich ML, et al. MMWR Morb Mortal Wkly Rep 2016;65:443–450. Available at: <http://dx.doi.org/10.15585/mmwr.mm6517e1>. Accessed October 18, 2017

Keast, SG (2010, October). Vote to Prior Authorize ProCentra and Second Opinion Process for ADHD/Narcolepsy Category[®]. Drug utilization report presented at the meeting of the Oklahoma Health Care Authority Drug Utilization Review Board, Oklahoma City, OK. Available online at: <https://www.okhca.org/about.aspx?id=9728>. Accessed May 30, 2017

Background


Estimates of Medication Treatment & Behavioral Therapy for ADHD



Treatment of attention-deficit/hyperactivity disorder among children with special health care needs. Journal of Pediatrics. Visser SN, Bitsko RH, et al. (2015). Available at: <http://dx.doi.org/10.1016/j.jpeds.2015.02.018>. Accessed October 18, 2017.

Background

Estimates of Medication Treatment & Behavioral Therapy for ADHD



Treatment of attention-deficit/hyperactivity disorder among children with special health care needs. Journal of Pediatrics. Visser SN, Bitsko RH, et al. (2015). Available at: <http://dx.doi.org/10.1016/j.jpeds.2015.02.018>. Accessed October 18, 2017.

Background

ADHD and Narcolepsy Product-based Prior Authorization (PA) Criteria

Tier 1	Tier 2	Tier 3	Special PA
Amphetamines			
<i>Short-Acting</i>			amphetamine (Evekeo™)
amphetamine (Adderall®)		dextroamphetamine (ProCentra®) sol	amphetamine (Mydayis™)
<i>Long-Acting</i>			lisdexamfetamine (Vyvanse®) capsules and chewable tablets
	Adderall XR® (brand only)	amphetamine/dextroamphetamine ER (generic Adderall XR)	Amphetamine (brand only)
	amphetamine ER ODT (Adzenys XR-ODT™)		dextroamphetamine (Dexedrine®) tabs
Methylphenidates			dextroamphetamine (Dexedrine®) spansules
<i>Short-Acting</i>			dextroamphetamine (ZenZedi®)
dexmethylphenidate (Focalin®)			dextroamphetamine (Dyanavel™ XR) Susp
methylphenidate (Methylin®)			methamphetamine (Desoxyin®)
methylphenidate (Ritalin®)			methylphenidate (Cotempla XR-ODT®)
<i>Long-Acting</i>			methylphenidate (Methylin®) chew tabs
methylphenidate CD	dexmethylphenidate ER (Focalin XR®)	methylphenidate ER (Concerta®)	methylphenidate (Methylin®) sol
methylphenidate ER (Aptensio XR™)	methylphenidate (Quilichew ER®) chew tabs	methylphenidate ER (Metadate ER®)	modafinil (Provigil®)
methylphenidate ER (Ritalin LA®)	methylphenidate (Quilivant XR®)	methylphenidate ER (Methylin ER®)	sodium oxybate (Xyrem®) sol
		methylphenidate ER (Ritalin SR®)	methylphenidate (Daytrana®)
Non-Stimulants			
atomoxetine (Strattera®)		clonidine ER (Kapvay®)	
guanfacine ER (Intuniv®)			

ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management. Pediatrics Oct 2011, peds.2011-2654. Available at: <http://pediatrics.aappublications.org/content/128/5/1007> . Accessed October 18, 2017.

Punja S, Shamseer L, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews 2016, Issue 2. Art. No.: CD009996. DOI: 10.1002/14651858.CD009996.pub2


Academic Detailing Program

ADHD Timeline

July 2015	Academic detailing pharmacist hired
September 2015	NaRCAD Interactive Training
October 2015	ADHD material development begins
November 2015	Article: Introduce AD service
December 2015	Provider calls begin
January 2016	Article: Pediatric ADHD treatment
January 2016	Provider visits begin
April 2017	ADHD Program evaluation begins

Academic Detailing Program

Targeted Counties



Academic Detailing Program

Program Evaluation: ADHD medication claims

	Age	Detailed	Non-Detailed
		% Change	% Change
Number of claims	0 - 4		
Cost of claims	0 - 4		
Number of claims	0 - 17		
Cost of claims	0 - 17		

Academic Detailing Program

Program Evaluation: ADHD medication claims

		Detailed	Non-Detailed
	Age	% Change	% Change
Number of claims	0 - 4	- 58.33 %	- 7.5 %
Cost of claims	0 - 4		
Number of claims	0 - 17		
Cost of claims	0 - 17		

Academic Detailing Program

Program Evaluation: ADHD medication claims

	Age	Detailed	Non-Detailed
		% Change	% Change
Number of claims	0 - 4	- 58.33 %	- 7.5 %
Cost of claims	0 - 4	- 69.28 %	+ 0.5 %
Number of claims	0 - 17		
Cost of claims	0 - 17		

Academic Detailing Program

Program Evaluation: ADHD medication claims

	Age	Detailed	Non-Detailed
		% Change	% Change
Number of claims	0 - 4	- 58.33 %	- 7.5 %
Cost of claims	0 - 4	- 69.28 %	+ 0.5 %
Number of claims	0 - 17	- 0.89 %	+ 3.32 %
Cost of claims	0 - 17		

Academic Detailing Program

Program Evaluation: ADHD medication claims

	Age	Detailed	Non-Detailed
		% Change	% Change
Number of claims	0 - 4	- 58.33 %	- 7.5 %
Cost of claims	0 - 4	- 69.28 %	+ 0.5 %
Number of claims	0 - 17	- 0.89 %	+ 3.32 %
Cost of claims	0 - 17	+ 1.37 %	+ 10.05 %


Academic Detailing Program

Program Evaluation: ADHD medication claims

		Detailed	Non-Detailed
	Age	% Change	% Change
Number of claims	0 - 4	- 58.33 %	- 7.5 %
Cost of claims	0 - 4	- 69.28 %	+ 0.5 %
Number of claims	0 - 17	- 0.89 %	+ 3.32 %
Cost of claims	0 - 17	+ 1.37 %	+ 10.05 %
Cost of claims	all	+ 2.03 %	+ 6.26 %

Academic Detailing Program

Program Evaluation: ADHD medication cost per claim by month



Academic Detailing Program

Program Evaluation: Program Feedback

I intend to:	Agree or Strongly Agree	Neither	Disagree or Strongly Disagree
recommend this program to colleagues	89 %	11 %	0 %
participate in future topics	89 %	9 %	2 %

Academic Detailing Program

Making AD Programs Sustainable

- Measurable and meaningful benchmarks
 - Clinical value
 - Financial value

Acknowledgements

- **Oklahoma HealthCare Authority:**
 - Nancy Nesser, Pharm.D., J.D., Pharmacy Director
- **University of Oklahoma, College of Pharmacy**
 - **Pharmacy Management Consultants (PMC):**
 - Terry Cothran, D.Ph., PMC Director
 - Bethany Holderread, Pharm.D., DUR Clinical Coordinator
 - **College Faculty and Staff:**
 - Shellie Keast, M.S., Pharm.D., Ph.D., Assistant Professor
 - Tammy Lambert, Pharm.D, Ph.D., Clinical Assistant Professor
 - Timothy Pham, Pharm.D, Ph.D., Research Fellow
 - David George, Pharm.D, Ph.D., Research Fellow
 - Christina Bulkley, Pharm.D, Ph.D. candidate

Questions